Hematology Special Issue

For some patients with myeloma, new targeted drugs may be an alternative to stem cell transplant.

Patients taking novel treatments for CLL, and their caregivers, should know which side effects to expect — and recognize when they become emergencies.

A study of acute lymphoblastic leukemia across the age spectrum is showing that some pediatric regimens can be successful in adults.

Two posters presented at the annual meeting of the American Society of Hematology discussed patient-reported outcome measures and quality-of-life indicators as supportive tools for treatment in individuals being treated for acute myeloid leukemia and myelodysplastic syndrome.

Four new drugs, and novel treatment combinations, are further extending life expectancy for patients with multiple myeloma.

Only 30 percent of survivors at high risk for cardiac damage adhered to long-term recommendations including an echocardiogram, electrocardiogram or multigated acquisition scan.

Multiple myeloma begins with a single precancerous plasma cell that multiplies uncontrollably and can eventually cause bone lesions and anemia.

Paring down treatment for Hodgkin lymphoma may reduce the risk of long-term side effects. Minimizing without hurting cure rates is the challenge.

Inspired by Those in its Pages, CURE Hosts Events That Highlight, Bolster the Work of Patient Advocates